Newsfeeds Archive - Page 2 of 7

2 minute read

Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results

September 26, 2:31 PM

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

CYBN

4 minute read

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More

By Lara Goldstein

September 26, 9:28 AM

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

ATAI

2 minute read

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression

By Lara Goldstein

September 21, 10:04 PM

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)

CYBN

2 minute read

Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie’s $100M Pledge Update

By Lara Goldstein

September 18, 3:10 PM

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

ATAI

2 minute read

Cybin’s Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT

By Lara Goldstein

September 5, 2:48 PM

The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and their pharmaceutical compositions with exclusivity until 2041.

CYBN

3 minute read

Psyched: Three Noteworthy Psychedelics M&As, Colorado’s Regulations, Exclusive Financing & More

By Lara Goldstein

September 5, 10:07 AM

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

ATAI

2 minute read

Mindset Pharma’s $60M Acquisition, Otsuka’s Leap Into Next-Gen Psychiatry Solutions

By Lara Goldstein

August 31, 1:54 PM

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka Pharmaceutical Co. in an all-cash transaction for approximately $60 (CA$80) million.

CYBN

2 minute read

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M

By Lara Goldstein

August 29, 2:31 PM

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million.

CYBN

2 minute read

Cybin’s Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

By Lara Goldstein

August 28, 1:38 PM

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

CYBN

7 minute read

Cybin To Acquire Small Pharma Inc.; Small Pharma Shareholders Will Receive 0.2409 Common Shares In The Capital Of Cybin; Exchange Ratio Implies Consideration Of ~$0.10 Per Small Pharma Share

By Happy Mohamed

August 28, 10:52 AM

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated

CYBN